Moderna and Medison Pharma partner to commercialize Moderna’s COVID-19 vaccine across Central Eastern Europe and Israel
CAMBRIDGE, Mass. and ZUG, Switzerland, June 7, 2021 /PRNewswire/ — Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, today announced a new agreement to commercialize the Moderna COVID-19 Vaccine across Central Eastern Europe and Israel. The agreement covers the following countries: Poland, Czech Republic, Romania, […]
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces the signing of a distribution agreement with Medison Pharma Canada (“Medison”) to distribute […]
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel DUBLIN, Ireland, and Boston MA, February 4, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces the signing of multi-regional distribution agreements […]
Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
SOUTH SAN FRANCISCO, Calif. and PETACH TIKVA, Israel, Nov. 23, 2020 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submission (NDS) for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments. […]
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement
PETACH TIKVA, Israel and WALTHAM, Mass., Nov. 6, 2020 /PRNewswire/ — Medison Pharma, a leading international commercial partner for highly innovative therapies, today announced an exclusive distribution agreement with Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor (GIST). GIST is a cancer that occurs in the gastrointestinal tract, most commonly […]
Medison Pharma and Alpha Tau Medical Announce a Collaboration in the Oncology Field in Central and Eastern Europe
PETAH-TIKVA, Israel, June 15, 2020 /PRNewswire/ — Medison Pharma Trading AG, a fully owned subsidiary of Medison Pharma Ltd., and Alpha Tau Medical Ltd., the developer of a breakthrough alpha-radiation cancer therapy “Alpha DaRT,” are pleased to announce an exploratory collaboration in the oncology field in Central and Eastern Europe. Medison is a specialized pharmaceutical and biotech company focused […]
BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel
CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and Medison Pharma Ltd., a leading global commercial partner for biotech and pharma companies that […]
Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT
TEL AVIV, Israel, April 7, 2020 /PRNewswire/ — Alpha Tau Medical– the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, and Medison Canada – a fully owned subsidiary of Medison Pharma, are pleased to announce that they have entered into an exclusive distribution arrangement. Medison is a specialized pharmaceutical and biotech company purely focused on licensing highly innovative, […]
BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A
BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD) Type A, and Medison Pharma Ltd., a leading commercial biotech partner that operates in Israel, Canada and Central and Eastern European countries, have entered into an […]
Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel
ZUG, Switzerland & PETACH TIKVA, Israel–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison […]